Genocea Biosciences (GNCA) Tops Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. UNH
7. CVS
8. SBUX
9. AXP
10. ZETA

Go back to Genocea Biosciences (GNCA) Tops Q2 EPS by 5c

Genocea Reports Second Quarter 2016 Financial Results

August 4, 2016 7:30 AM EDT

CAMBRIDGE, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported corporate highlights and financial results for the second quarter ended June 30, 2016.

"Full results from the Phase 2 dose optimization trial evaluating GEN-003, our immunotherapy for genital herpes, were showcased at ASM Microbe 2016 in June. The data show that a single course of treatment has significant and durable effects on both HSV-2 viral activity and genital herpes clinical disease for at least 12 months post dosing. Based on this clinical profile, we... More